biotech · Pulmonary Arterial Hypertension · Pulmonary Arterial Hypertension (PAH) · IKT
Inhibikase Therapeutics
Inhibikase Therapeutics is a biotech organization headquartered in Wilmington, USA. It trades on NYSE under ticker IKT. Primary therapeutic focus areas include Pulmonary Arterial Hypertension, Pulmonary Arterial Hyperten
Wilmington, USA HQ
29 Employees
Public company Type
IKT · NYSE Ticker
Company details
- Status
- Public
- HQ
- Wilmington, USA
- Employees
- 29
- Programs
- 4
- Drugs
- 5
- Patents
- 9
IkT-001Pro
Phase 2 · small molecule · Pulmonary Arterial Hypertension (PAH)
IkT-001Pro for Pulmonary Arterial Hypertension (PAH) is a Phase 2 program (small_molecule) at Inhibikase Therapeutics with 1 ClinicalTrials.gov record(s).
Internal code IkT-001Pro-702
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Inhibikase Therapeutics
- Phase
- Phase 2
- Modality
- small_molecule
- Indication
- Pulmonary Arterial Hypertension (PAH)
- Status
- terminated
- Trials
- 1